Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani
N
N
Department of Surgery, State University of New York Health Science Center at Brooklyn 11203, USA.
Hong
J H
JH
DiBenedetto
A
A
Clayton
R
R
Miles
A M
AM
Markell
M S
MS
Distant
D A
DA
Fleishhacker
J
J
Sommer
B G
BG
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001706:Biopsy; D001803:Blood Transfusion; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D006085:Graft Survival / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D003404:Creatinine; D008775:Methylprednisolone